Revolutionizing Genetic Therapy Development & Delivery to the Eye The Race Is On; Luxturna Remains the Only Approved Gene Therapy for the Eye, Who Will Be the Next? The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced i
13-16 September 2022